Mariana Lenharo in Nature:
The quest for GLP-1 drugs that can treat brain disorders is getting a fresh infusion of energy and funding. Pharmaceutical companies have plunged into developing GLP-1-related compounds to treat addiction, schizophrenia, depression and other conditions — building on years of work by academic scientists.
Last month, pharma giant Eli Lilly presented the first clinical results of brenipatide, a compound related to the company’s blockbuster obesity drug tirzepatide, for treatment of alcohol use disorder. Last week, biotechnology firm Kariya Pharmaceuticals shared early clinical results of a similar compound called KP405 for Parkinson’s disease. And biotechnology company Baseline Therapeutics plans to start a clinical trial in early 2027 of a GLP-1 compound for alcohol use disorder.
More here.
Enjoying the content on 3QD? Help keep us going by donating now.